TrialBlood2021

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.

Austin G Kulasekararaj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.